LDL-apheresis (LDLa) efficacy in the treatment of symptomatic HyperLp(a)lipoproteinemia -HyperLp(a)- has been studied in a multicentre trial. After 3.1 +/- 2.7 years of weekly and biweekly treatment, the data from 19 patients (males: 12; females: 7; aged 53.8 +/- 9.3 years; mean body mass index: 24.6 +/- 2.3 Kg/m(2)) were evaluated. Data were collected using the same questionnaire shared by 5 participating centres. A total of 2331 procedures were performed. A mean of 3593.7 +/- 800.3 ml of plasma or 8115.3 +/- 2150.1 ml of blood, depending upon the technique used (H.E.L.P., D.A.LI., Dextransulphate, Lipocollect 200), was regularly treated on average every 10.1 +/- 2.6 days. Baseline mean Lp(a) levels were 172.3 +/- 153.8 mg/dL. The mean pre...
Abstract Elevated lipoprotein(a) (Lp(a)) has emerged as an important independent cardiovascular risk...
BACKGROUND AND AIMS In 2008, the National Institute of Health and Care Excellence in the UK recom...
Lipid apheresis is used to treat patients with severe hyperlipidemia by reducing low-density lipopro...
Background/aims: To assess LDL-apheresis efficacy to lower Lp(a) and to compare the effects of Usual...
Therapeutic means to lower Lp(a) are limited. The most effective method to reduce plasma Lp(a) conce...
Lipoprotein apheresis (LA) is the elective therapy for homozygous and other forms of Familial Hyperc...
Lipid-apheresis (LA) and LDL-apheresis (LDLa) are extracorporeal techniques which permit the unselec...
Ulrich Julius Lipidology and Center for Extracorporeal Therapy, Department for Internal Medicine III...
Lipoprotein apheresis (LA) is a therapeutic approach to save the lives of patients who are at an ext...
AbstractLow-density lipoprotein (LDL)-apheresis is a Food and Drug Administration–approved treatment...
Aim: To assess the safety and efficiency of H.E.L.P.-apheresis and cascade lipid-filtration in the t...
Background-Lipoprotein(a) (Lp(a)) hyperlipoproteinemia is a major risk factor for cardiovascular dis...
OBJECTIVES: Lipoprotein(a) (Lp(a)) is an independent cardiovascular (CV) risk factor, predisposing t...
An elevation of lipoprotein(a) (Lp(a)) is an internationally recognized atherogenic risk factor, doc...
Lipoprotein-apheresis (LA) is an extracorporeal technique which permits the unselective or specific ...
Abstract Elevated lipoprotein(a) (Lp(a)) has emerged as an important independent cardiovascular risk...
BACKGROUND AND AIMS In 2008, the National Institute of Health and Care Excellence in the UK recom...
Lipid apheresis is used to treat patients with severe hyperlipidemia by reducing low-density lipopro...
Background/aims: To assess LDL-apheresis efficacy to lower Lp(a) and to compare the effects of Usual...
Therapeutic means to lower Lp(a) are limited. The most effective method to reduce plasma Lp(a) conce...
Lipoprotein apheresis (LA) is the elective therapy for homozygous and other forms of Familial Hyperc...
Lipid-apheresis (LA) and LDL-apheresis (LDLa) are extracorporeal techniques which permit the unselec...
Ulrich Julius Lipidology and Center for Extracorporeal Therapy, Department for Internal Medicine III...
Lipoprotein apheresis (LA) is a therapeutic approach to save the lives of patients who are at an ext...
AbstractLow-density lipoprotein (LDL)-apheresis is a Food and Drug Administration–approved treatment...
Aim: To assess the safety and efficiency of H.E.L.P.-apheresis and cascade lipid-filtration in the t...
Background-Lipoprotein(a) (Lp(a)) hyperlipoproteinemia is a major risk factor for cardiovascular dis...
OBJECTIVES: Lipoprotein(a) (Lp(a)) is an independent cardiovascular (CV) risk factor, predisposing t...
An elevation of lipoprotein(a) (Lp(a)) is an internationally recognized atherogenic risk factor, doc...
Lipoprotein-apheresis (LA) is an extracorporeal technique which permits the unselective or specific ...
Abstract Elevated lipoprotein(a) (Lp(a)) has emerged as an important independent cardiovascular risk...
BACKGROUND AND AIMS In 2008, the National Institute of Health and Care Excellence in the UK recom...
Lipid apheresis is used to treat patients with severe hyperlipidemia by reducing low-density lipopro...